Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema

Diabetic Macular Edema Clinical Trial

Official title:

Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05728476
• Other study ID #: TianjinMUEHhbj111
• Status: Recruiting
• Phase: N/A
• Start date: March 5, 2024
• Est. completion date: September 5, 2026

Study information

• Verified date: October 2023
• Source: Tianjin Medical University Eye Hospital
• Contact: Bojie Hu
• Phone: 13612130943
• Email: bhu07[@]tum.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some patients do not respond well to anti-VEGF agents and often require multiple injections, which increases the psychological and economic burden of patients. Microinvasive pars plana vitrectomy (PPV) has been proven to be safe and effective for refractory DME. However, there are few studies on treatment-naïve DME. The purpose of this study is to explore whether early PPV combined with internal limiting membrane (ILM) peeling can reduce the treatment burden of DME patients, prevent vision loss, and maintain long-term stabilization of diabetic retinopathy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 102
• Est. completion date: September 5, 2026
• Est. primary completion date: September 5, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years of age

• Patients and their families fully understand the research and sign the informed consent form

• Diagnosed with type 1 or 2 diabetes mellitus

• Hemoglobin A1c (HbA1c) of less than 10% within 3 months

• Clear media for adequate OCT and optical coherence tomography angiography (OCTA) images

• Treatment-naïve DME diagnosed clinically

• Central subfield thickness (CST) of >300µm and intra- or subretinal fluid seen on (spectral-domain) SD-OCT

• Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA between 24 and 73 letters on the day of randomization

• Treatment within 12 months of DME diagnosis

• No contraindication of vitrectomy or conbercept intravitreal injection

Exclusion Criteria:

• Any previous DME treatment (i.e. anti-VEGF injections, intraocular corticosteroids, macular photocoagulation)

• Macular edema caused by other disease (i.e. neovascular age-related macular degeneration, retinal vein occlusion, uveitis)

• Any previous intraocular surgeries (cataract surgery performed at least 3 months before study entry will not be exclusionary)

• Vision loss caused by other ocular disease (i.e. cataract, proliferative diabetic retinopathy, glaucoma, high myopia)

• A follow-up duration of less than 12 months

• Severe dysfunction of the heart, liver, kidney, lung and other organs

Related Conditions & MeSH terms

• Conbercept
• Diabetic Macular Edema
• Edema
• Macular Edema
• Pars Plana Vitrectomy

Intervention

Procedure:
• Vitrectomy combined with ILM peeling
Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.

Drug:
• Conbercept intravitreal injection
Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.

Locations

Country	Name	City	State
China	Tianjin medical university eye hosipital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Eye Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best corrected visual acuity change (BCVA)	Early Treatment Diabetic Retinopathy Study (ETDRS) Alphabet Chart	1, 3, 6, 12 month postoperatively
Primary	Central subfield thickness (CST) change	Three-dimensional spectral domain optical coherence tomography (SD-OCT)	1, 3, 6, 12 month postoperatively
Secondary	The stage of diabetic retinopathy (DR)	The grading and classification of DR will follow the International Clinical Diabetic Retinopathy and Diabetic Macular Oedema Disease Severity Scales. Ultra-wide field fundus photography will help investigators grade diabetic retinopathy.	12 month postoperatively
Secondary	Cost-effectiveness analysis	The incremental cost-effectiveness ratio (ICER) is used as the evaluation index in cost-effectiveness analysis. The average cost of the two groups of treatments is taken as willingness to pay (WTP). If ICER is less than WTP, the treatment scheme is cost-effective.	12 month postoperatively
Secondary	Vision-related quality of life questionnaire	The National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) will be used to evaluate the vision-related quality of life. Scores range from 0 to 100, and lower scores indicate a poorer quality of life.	6, 12 month postoperatively
Secondary	Biomarkers of optical coherence tomography (OCT)	Scanning was centred on the macular fovea with a scan length of 6 mm. The resolution was 5 µm, the scan depth was 4 mm, and the scan mode was horizontal linear scanning of 512×128.	1, 3, 6, 12 month postoperatively
Secondary	Biomarkers of OCT angiography (OCTA)	The scanning area, centred on the fovea, was captured in 3×3 mm sections with a resolution of 304×304 pixels.	1, 3, 6, 12 month postoperatively
Secondary	Occurrence rates of re-treatment	Pro re nata conbercept treatment will be performed if the following criteria are met: (1) existence of recent or persisting cystoid retinal lesions; (2) a decrease of no less than 5 ETDRS letters in BCVA; and (3) an increase of 50 µm or more in CST compared with the best value previously achieved.	12 months postoperatively
Secondary	Occurrence rates of adverse events	Ocular hypertension, progression of cataract, corneal abrasion, retinal injury, hyphaemia, uveitis or inflammatory reaction, and endophthalmitis.	12 months postoperatively